NKTR Stock Clocks Best Day In Over 2 Months As Investors Await Upcoming Clinical Data In Eczema
Nektar Therapeutics has multiple near-term catalysts in place, some expected as early as this month. The company plans to begin its global late-stage program in moderate-to-severe atopic dermatitis by the end of July 2026. In alopecia areata, a condition that causes hair loss, Nektar reported positive results from its mid-stage study in April 2026. In … Read more